Background
Sleep disruption is a major public health issue and may increase the risk of mortality by ten-folds if an individual is sleeping less than 6 h per night. Sleep has changed dramatically during to the COVID-19 pandemic because COVID symptoms can lead to psychological distress including anxiety. Hericium erinaceus mycelium has been widely investigated in both the in vivo studies and clinical trials for its neuroprotective functions because the mycelium contains hericenones and erinacines, which synthesize the nerve growth factor and brain-derived neurotrophic factor (BDNF). Recent in vivo reports have shown showed that erinacine A-enriched Hericium erinaceus mycelium can modulate BDNF/TrkB/PI3K/Akt/GSK-3β pathways to induce an antidepressant-like effect. A large body of evidence indicates that erinacine can pass the blood-brain barrier and suggests its neuroprotective function in both peripheral and central nervous systems. Thus, Hericium erinaceus mycelium may be a dual-function supplement for sleep disruption improvement while sustaining anxiolytic effects.
Method
To simulate the condition of sleep disruption, the mice were subjected to the tail suspension test (TST) for 15 min every day during the same period for nine consecutive days. Two different doses (75 and 150 mg/kg) of Hericium erinaceus mycelium were administered orally 20 min prior to the TSTs before entering the light period of 12:12 h L:D cycle. All sleep-wake recording was recorded for 24 h using electroencephalogram and electromyogram. The elevated-plus-maze and open-field tests were conducted to record the behavior activities.
Results
Consecutive TSTs prior to the light period could cause significant sleep disturbance and anxiety behavior in the elevated-plus-maze experiments. Results showed that administration with Hericium erinaceus mycelium at 150 mg/kg ameliorated the rodent anxiety (p < 0.05) and reversed the TST-induced NREM sleep disturbance in the dark period.
Conclusion
This is the first in vivo study suggesting that Hericium erinaceus mycelium has a dual potential role for anxiety relief through improving sleep disruptions.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12906-021-03463-3.
Sleep deprivation is an important public issue in many countries. Statistics have shown that approximately 83.6 million adults in the United States sleep less than 7 h a day [1]. Sleep deprivation often causes a lack of energy restoration and metabolite clearance in the brain, which is crucial in sustaining brain function and behaviors [2]. Poor sleep quality as defined by the National Sleep Foundation [3], can often occur from working pressure, stress, anxiety, and financial burden; it eventually affects the formation of long-term memory [4]. Sleep deprivation is believed to be closely related to anxiety levels [5]. Nevertheless, the recent pandemic issue of COVID-19 causing stress and anxiety at the same time have greatly altered the sleep quality [6].
Sleep is divided into two distinct states: rapid eye movement (REM) sleep and non-rapid eye movement (NREM) sleep [5, 7]. A study showed that changes in NREM sleep often correlate with anxiety levels in mice [8]. On the other hand, REM sleep latency is a feature of the early symptoms in depression [9]. Nerve growth factor (NGF) is a key and important modulator in suppressing wakefulness and contributes to the generation of REM sleep [10]. Nevertheless, once anxiety symptoms occur from sleep deprivation, this kind of vicious sleep disruption will hamper the therapeutic efficacy in anxiety patients. Therefore, proper and safe supplementary nutrients are needed for anxiety relief while improving sleep patterns in anxious patients [11].
Hericium erinaceus (H. erinaceus) has long been used as a medicinal-culinary mushroom [12], which showed various health benefits including anti-aging [13], antioxidative [14], anticancer [15], and neuroprotection [16]. Studies found that the H. erinaceus cultured extract contains about more than 15 compounds of the active cyathin diterpenoid [17] with potential neuroprotective effects in the treatments of Alzheimer’s and Parkinson’s diseases [18]. Incubation with H. erinaceus erinacine compounds increases NGF gene expression in the human astrocytoma cell line 1321 N1 [19]. Erinacine A-enriched H. erinaceus mycelium can induce an antidepressant-like effect by modulating the BDNF/TrkB/PI3K/Akt/GSK-3β pathway in vivo [20]. An in vivo biodistribution study found that erinacine from the H. erinaceus mycelium can be found in the brain tissue indicating its capability to pass the blood-brain barrier and exert a neuroprotective function [21]. A double-blind placebo-controlled study further showed that consumption of three H. erinaceus mycelium capsules per day (containing 5 mg/g of erinacine A) can prevent early Alzheimer’s disease versus a placebo group [22]. All these studies suggest that H. erinaceus mycelium is safe and effective at improving life quality for patients with neurodegeneration.
Despite the accumulated evidence that H. erinaceus has in terms of anti-depression and memory improvement [23], there is no report to date that has investigated the potential of H. erinaceus mycelium for sleep deprivation with early anxiety symptoms. The aim of this study is to investigate the alterations of behavior activities and monoamines in a sleep disrupted mouse model treated with nutrient H. erinaceus mycelium. We then evaluated its potential as an anxiety relief supplement that can improve sleep.
Preparation of the H. erinaceus mycelium
The H. erinaceus mycelium was prepared according to previous studies [24]. In brief, the H. erinaceus strain was purchased from the Bioresources Collection and Research Center in the Food Industry Research and Development Institute (BCRC 35669; Hsinchu, Taiwan). Initial culture was grown in a 2-L flask using a shaker at ~ 120 rev/min at 25 °C for 5 days containing growth medium at pH 4.5 (0.05% MgSO4, 0.25% peptone, 0.5% soybean powder, 4.5% glucose, and 0.25% yeast extract). The seeding medium is then transferred to 500-L fermenters for 5 days and scaled up to 20-ton fermenters for another 12 consecutive days. This large-scale process is then harvested and lyophilized to remove excessive water. The final product is ground into powder form and stored in desiccators at room temperature for in vivo experiments. To evaluate the main chemical composition of Hericium erinaceus Mycelium, high-performance liquid chromatography (HPLC) was used to evaluate the active peaks’ contents. Major composition such as erinacine A and erinacine C were analyzed according to previous studies with minor modifications.
Feeding condition
All animal experiments were carried out in compliance with the ARRIVE guidelines and were approved by the National Taiwan University Institutional Animal Care and Use Committee (approval number NTU-107-EL-00182). The C57BL/6 mice used in this study were obtained from BioLASCO (TaiwanCo., Ltd.). Oral gavage was employed for the drug delivery. Two different doses of H. erinaceus mycelium (75 and 150 mg/kg) were administered. All administrations of substances were administered 20 min prior to the tail suspension test (TST) before entering the light period of 12:12 h L:D cycle.
Tail suspension test (TST)
The TST was executed from the beginning of the light period and lasted for 15 min every day and the procedure was performed for nine consecutive days during the same time point. Noise and light were avoided while the tail suspension test experiment was conducted. The environment background was set to the white color during the behavioral task to enhance the contrast of the mice. During the TSTs, the struggle movement was determined offline by EthoVision XT software (Noldus Information Technology, Inc., USA). The TST is one of the most widely used models to assess depression in rodents. Previous studies have shown that the TSTs is an acute stressor that causes sleep disruptions in mice
Elevated plus maze (EPM) behavior test
The EPM was conducted with a similar method as described previously [20]. In brief, the apparatus was placed at a height 50 cm above the floor with two open arms (50 cm × 9 cm) and two enclosed arms (50 cm × 9 cm × 5 cm). The common central area is 9 × 9 cm. Time spent in both open and closed arms was recorded by the video camera. All paths were wiped with 70% ethanol between each individual test to avoid disturbance due to the scent of the previously tested animal.
Open field test (OF)
The open field test (OF) was conducted in an acrylic box (60 cm × 60 cm × 20 cm) with a floor divided equally with 96 squares. A digital video camera was fixed vertically above the cage to record the mouse activities. For every mouse analysis, the cage was cleaned with water to remove scent of the previously tested animal to prevent any bias.
Sleep recording and analysis
Two wire electroencephalogram (EEG) electrodes were surgically implanted on the right frontal lobe and the left occipital lobe. The occipital electrode served as the reference. Two electromyogram (EMG) electrodes were inserted into the neck muscle. The sleep-wake activity was recorded for 24 h after the manipulations. Based on the previous study [27], the animal’s vigilance states were classified to NREM sleep, REM sleep, or wakefulness. Briefly, NREM sleep was characterized by large-amplitude EEG slow waves, high power density values in the delta frequency band (0.5–4.0 Hz), and a relaxed muscle tone from EMGs. During REM sleep, the amplitude of the EEG was reduced, and the predominant EEG power density occurs within the theta frequency (6.0–9.0 Hz). The EMGs exhibit muscle atonia with low EMG amplitudes.
The animals are generally active during wakefulness. There are protracted body movements with robust EMG amplitudes. The amplitude of EEGs is like that observed during REM sleep, but power density values in the delta frequency band are generally greater than those in theta frequency band. The percentage of NREM sleep and REM sleep, slow wave activity during the NREM sleep, and sleep architectures were determined. Animals were housed in individual recording cages in an isolated animal room with the temperature maintained at 23 ± 1 °C and a light:dark (L:D) cycle of 12:12-h (20 W × 6 tubes illumination). Food and water were available ad libitum.
Plasma dopamine analysis
After the behavioral tests, all mice were sacrificed by perfusion with carbon dioxide (CO2) and decapitation. The blood was quickly obtained from the mouse’s heart and stored at − 80 °C until the dopamine levels were measured. The enzyme-linked immunosorbent assay (ELISA) kit for dopamine was obtained from Wuhan Fine Biotech Co., and the detailed procedure followed the manufacturer’s instructions. The absorbance was determined by ELISA microplate (Multiskan EX, Thermo Electron Corp., Waltham, MA) with an O.D. absorbance at 450 nm. The sensitivity is < 0.938 ng/ml, and the assay range is between 1.56 and 100 ng/ml. The intra-assay CV is < 8% and the inter-assay CV is < 10% (manufacturer’s specifications).
Western blot analysis
The mouse brain tissue was homogenized with RIPA buffer containing phosphatase and protease inhibitors. The total protein content was quantified using Pierce™ BCA Protein Assay Kit (23,227, Thermo, USA). Protein lysates were separated with 10% SDS–PAGE gel by electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes (ISEQ00010, Millipore, USA) using electroblotting transfer tank (Bio-Rad). The PVDF membrane was blocked with 5% non-fat milk powder in tris-buffered saline with Tween 20 (TBST). Primary antibodies, including BDNF (ab108319; Abcam) and GAPDH (SC-32233; Santa Cruz Biotechnology), were incubated with the membranes diluted at 4 °C overnight. Secondary antibody (65–6120, 62–6520; Invitrogen) was applied and the bound-protein bands were visualized using enhanced chemiluminescence (K-12045-D50, Advansta, USA) and quantified using detection system (BIO-RAD ChemiDoc XRS+, USA). The target protein relative intensity was normalized against GADPH.
Statistical analysis
The percentages of time spent in NREM sleep, REM sleep, the immobility during the TSTs, the open arm during EPM, and the inner area during the OF were represented as the mean ± standard error of mean (SEM) with indicated sample sizes. This study used two-way analysis of variance (ANOVA) to measure the difference between each group with a post-hoc comparison. A level of p < 0.05 was considered to indicate a statistically significant difference.
Results
The effects of the consecutive TSTs on sleep-wake activity
he consecutive 9-day TSTs resulted in an increase in animal immobilization by 40% (Fig. 1) demonstrating that continuous stress can lead to a more emotional helplessness behavior in depression.
We manipulated the TSTs prior to the light period to further evaluate whether the consecutive TSTs affects sleep-wake activity. The results showed that the TSTs conducted before the light period significantly decreased NREM sleep in the subsequent dark period (hours 13–24) (Fig. 2A), and REM sleep was significantly increased in the late stage of the dark period (hours 20–22) (Fig. 2B).
The analytical results indicate that consecutive TSTs at the beginning of the light period could induce sleep disturbance. The TSTs during the light period could cause a decline in NREM sleep and a rise in the REM sleep in the subsequent dark period.
The effects of H. erinaceus mycelium on sleep-wake activity
The H. erinaceus mycelium was given prior to the light period of a 12:12 h L:D cycle in the TSTs-treated mice. The results showed that both 75 mg/kg and 150 mg/kg of H. erinaceus mycelium could increase the percentage of time spent in NREM sleep during the dark period. The effect of H. erinaceus mycelium on NREM increases showed up at the late stage of the dark period (hours 19–24) in the low dose (75 mg/kg) group (Fig. 3A). The rise of NREM sleep appeared nearly during the 12 h dark period (hours 15–24) in the high-dose (150 mg/ kg) group (Fig. 3B). Nevertheless, administration of 75 mg/kg H. erinaceus mycelium exhibited no effect on TSTs-induced increase of REM sleep; meanwhile there was a REM sleep decline at hour 20 in the group treated with 150 mg/kg of H. erinaceus mycelium versus the TSTs group (Figs. 3C and D).
These results suggest that the high dose (150 mg/kg) of H. erinaceus mycelium could block the TSTs-induced decreases of NREM sleep; it also increased REM sleep in the dark period. However, the low dose (75 mg/kg) of H. erinaceus mycelium could only block the TSTs-induced decreases of NREM sleep in the dark period.
The effects of H. erinaceus mycelium on EPM activity
In the EPM experiments, H. erinaceus mycelium was administered prior to the light period of the 12:12 h L:D cycle. The results showed that 150 mg/kg of H. erinaceus mycelium could increase the proportion of time spent in the open arms compared with that of the TST+ group (Fig. 4). However, lower doses of H. erinaceus mycelium (75 mg/kg) showed no anxiolytic effects.
The effects of H. erinaceus mycelium in OF test
In the OF test experiments, H. erinaceus mycelium was administered prior to the light period of the 12:12 h L:D cycle. The results showed that 150 mg/kg of H. erinaceus mycelium could increase the proportion of time spent in the open arms compared with that of the TST+ group (Fig. 5). However, lower doses of H. erinaceus mycelium (75 mg/kg) also showed no anxiolytic effects.
The effects of H. erinaceus mycelium in plasma dopamine activity and brain tissue BDNF
In the plasma neurotransmitter analysis, H. erinaceus mycelium was administered prior to the light period of the 12:12 h L:D cycle. When TSTs were conducted, the plasma dopamine levels decreased significantly by 26.5%. Low dose of H. erinaceus mycelium has no effect in the recovery of the dopamine levels. However, the high dose of H. erinaceus mycelium significantly recovered the plasma dopamine concentrations back to normal levels (435.882 ± 32.098 ng/mL, Fig. 6). The mouse brain BDNF expression was also evaluated by western blot analysis. TSTs group showed a significant reduction of BDNF expression after continuous stress. At high dose of H. erinaceus mycelium treatment, an increase in BDNF expression can be observed when compared with the control group (Supplementary Fig. S1).
HPLC analysis of the components from H. erinaceus mycelium
The identification of the erinacine component was extracted using 85% ethanol from the H. erinaceus mycelium (Fig. 7). The erinacine A and erinacine C was confirmed by comparing the characteristics of the spectrum of the sample peak with those of the standard peak (blue line, erinacine A; purple line, erinacine C) with a yield of 7.20 mg/g and 3.35 mg/g, respectively.
